Semaglutide (Rybelsus®) receives FDA approval as first line treatment for Type 2 Diabetes Mellitus

Novo Nordisk
Semaglutide, available in oral and subcutaneous dosage forms, is a selective glucagon-like peptide-1 receptor agonist with 3 main mechanisms of action.

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: